Arcus Biosciences (RCUS) announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. Leerink Partners and Goldman Sachs & Co. are acting as joint book-running managers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
- Arcus Biosciences price target raised to $35 from $33 at Wedbush
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
- Arcus Biosciences Reports Promising Q3 2025 Results